Table 2.

Comparison of patient characteristics between those with DLM identified with image guidance assistance and those with DLM not identified with image guidance

	Patients with DLM identified with image guidance (n = 5)	Patients with DLM not identified with image guidance (n = 9)	p value
Age (years), median (range)	61 (59–73)	52 (30–75)	0.205
Sex
Male	2 (40%)	2 (22%)	0.480
BMI, median (range)	26.6 (19.3–31.3)	23.0 (19.9–25.6)	0.463
CRS	2 (2–3)	3(2–3)	0.101
Months of neoadjuvant chemotherapy, median (range)	7 (6–17.5)	4 (3–16)	0.050
Chemotherapy regimen
Included 5-FU	5 (100%)	9 (100%)	-
Included oxaliplatin	5 (100%)	8 (89%)	0.439
Included irinotecan	2 (40%)	1 (11%)	0.207
Included hepatic arterial infusion pump	2 (40%)	1 (11%)	0.207
DLMs per patient, median (range)	3 (2–4)	3 (1–8)	0.784
Months between preoperative imaging showing DLM and DOS, median (range)	7.1 (2.6–18.7)	5.6 (4.5–12.4)	0.386

DLM disappearing liver metastases, BMI body mass index, CRS colorectal risk score, 5-FU 5-fluorouracil, DOS date of surgery